Integrated systems biology approach reveals the potential mechanism of Guanxinning in treating coronary heart disease complicated with major depressive disorder through S1PR3 regulation
This study identifies S1PR3 as a critical therapeutic target for the comorbidity of CHD and MDD. GXN has the potential to treat CHD and MDD by regulating S1PR3 expression levels. Although further validation through animal and cell-based experiments is needed, our findings provide a foundational understanding of the molecular mechanisms and highlight the therapeutic potential of GXN in dual heart therapy.
Authors
- Qing Miao (ORCID: https://orcid.org/0000-0002-3125-1238)
- Peijian Liu
- Qingmin Chu (ORCID: https://orcid.org/0000-0002-1144-5211)
- Yuling Zhang (ORCID: https://orcid.org/0000-0002-1404-6101)
- Kunsheng Wu
- Guiting Zhou (ORCID: https://orcid.org/0000-0001-7841-3460)
- Yujie Hua (ORCID: https://orcid.org/0009-0007-7879-1681)
- Rui Peng (ORCID: https://orcid.org/0009-0001-8062-9962)
- Chuchu Shen
- Wanwen Kong
Institutions
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- Computers in Biology and Medicine
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1016/j.compbiomed.2025.110456
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00